Clinical Trial Update: Open-label Safety of Sodium Zirconium Cyclosilicate for up to 12 Months in Japanese Subjects With Hyperkalemia [Phase 3]

View source ↗

Summary

Open-label safety study of sodium zirconium cyclosilicate in Japanese adults with hyperkalemia, up to 12 months (Phase 3; completed).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hyperkalemia

Drugs mentioned

• Sodium Zirconium Cyclosilicate (sodium zirconium cyclosilate)

Snippet

Sponsor: AstraZeneca | Conditions: Hyperkalemia | Phase 3 | Status: COMPLETED | Results posted: 2020-05-01